Company: argenx SE (“argenx” or “Company”) is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. The Company is transforming immunology and delivering medicines that help autoimmune patients get their lives back.  argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART (IV) and VYVGART Hytrulo (SC), the Company’s first-in-class neonatal Fc receptor blocker, currently approved for the treatment of generalized Myasthenia Gravis (gMG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and with the potential to treat patients across dozens of severe autoimmune diseases.